BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Özen A, Prachanronarong K, Matthew AN, Soumana DI, Schiffer CA. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. Crit Rev Biochem Mol Biol 2019;54:11-26. [PMID: 30821513 DOI: 10.1080/10409238.2019.1568962] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Shaqra AM, Zvornicanin SN, Huang QYJ, Lockbaum GJ, Knapp M, Tandeske L, Bakan DT, Flynn J, Bolon DNA, Moquin S, Dovala D, Kurt Yilmaz N, Schiffer CA. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun 2022;13:3556. [PMID: 35729165 DOI: 10.1038/s41467-022-31210-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: Structure, mechanism and inhibition. Enzymes 2021;50:301-33. [PMID: 34861941 DOI: 10.1016/bs.enz.2021.09.004] [Reference Citation Analysis]
3 Boonma T, Nutho B, Darai N, Rungrotmongkol T, Nunthaboot N. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. J Biomol Struct Dyn 2021;:1-12. [PMID: 33430709 DOI: 10.1080/07391102.2020.1869587] [Reference Citation Analysis]
4 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bafna K, White K, Harish B, Rosales R, Ramelot TA, Acton TB, Moreno E, Kehrer T, Miorin L, Royer CA, García-Sastre A, Krug RM, Montelione GT. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep 2021;35:109133. [PMID: 33984267 DOI: 10.1016/j.celrep.2021.109133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
6 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, Liu X, Zhan P. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514-40. [PMID: 33595031 DOI: 10.1039/d0cs01084g] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
8 Boonma T, Nutho B, Rungrotmongkol T, Nunthaboot N. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Comput Biol Chem 2019;83:107154. [PMID: 31751885 DOI: 10.1016/j.compbiolchem.2019.107154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chem Biol 2020;15:342-52. [PMID: 31868341 DOI: 10.1021/acschembio.9b00675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Meanwell NA, Georg GI, Wang S. The 2020 Nobel Prize in Physiology or Medicine. J Med Chem 2020;63:13197-204. [PMID: 33147952 DOI: 10.1021/acs.jmedchem.0c01877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]